Latest Headlines

Does Anemia Protect Children From Malaria?

It is well known that sickle cell trait can protect carriers from developing malaria; yet iron deficiency anemia offers a greater protective effect against malaria than sickle cell trait, according to research published in...

Online Exclusive

CMS Proposes New Reimbursement Rate for CAR T-Cell Therapies

The Centers for Medicare and Medicaid Services (CMS) has proposed a new system for calculating reimbursement rates for hospitals administering chimeric antigen receptor (CAR)...

28 Million Elective Surgeries Worldwide Estimated to be Delayed by COVID-19

A study published in the British Journal of Surgery estimates that 28.4 million elective surgeries worldwide could be canceled or postponed in 2020 because...

Cover Story

Predatory Publishing: The Dark Side of the Open-Access Movement

In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker side of scientific publishing: predatory publishing. This segment of the OA publishing movement is characterized by publishers that “unprofessionally exploit” the gold OA model (in which the final version of a manuscript is made freely available on publication), primarily for profit, according to Jeffrey Beall, MSLS, one of the most vigilant watchdogs of predatory publishing, and operator of the website Scholarly Open Access. Sometimes called “vanity presses,” these entities publish practically any materials that come their way, as long as authors are willing to pay a submission and publication fee. Critics – and they are legion...

Clinical News

Latest Videos

Constantine Tam: Zanubrutinib Active in Treatment-Naïve CLL/SLL

Constantine S. Tam, MBBS, MD, discusses findings from the phase III SEQUOIA trial, in which 92% of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma...

Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline...

Nearly half of patients treated with acalabrutinib plus venetoclax and obinutuzumab achieved a complete response with undetectable minimal residual disease. Benjamin L. Lampson, MD,...

David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML

Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman,...

Jacqueline Garcia: Evaluating Navitoclax for Myelofibrosis

Jacqueline S. Garcia, MD, shares results from a phase II study of navitoclax, an investigational disease-modifying therapy for the treatment of myelofibrosis, which appears...

On Location

On location

Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL/SLL

The availability of B-cell receptor inhibitors (BCRis) and other novel agents for the treatment of...
On location

Early-Phase Study Shows Promising Response Rates With Venetoclax Plus Navitoclax in ALL

Nearly half of patients with relapsed/refractory acute lymphocytic leukemia (ALL) had a complete response (CR)...
On location

Daratumumab-Based Induction and Response-Adapted Consolidation Induces MRD Negativity in Patients With Newly Diagnosed Myeloma

Induction therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) followed by autologous transplant and Dara-KRd...

Clarithromycin Improves Responses But Fails to Prolong Survival in Newly Diagnosed Myeloma

Adding the antibiotic clarithromycin to lenalidomide plus dexamethasone improved the response rate in patients with...
On location

Can Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Skip Radiation Therapy?

Results from the Intergroup National Clinical Trials Network (NCTN) study S1001 demonstrated that 89% of...

DDGP Versus SMILE: Comparing Regimens for Extranodal Natural Killer T-Cell Lymphoma

In patients with extranodal natural killer T-cell lymphoma (ENKTL), treatment with the chemotherapy regimen of...
Advertisement

Sign Up for our enewsletter!

Subscribe to our newsletter to receive the latest news, updates and online exclusive content.

8,802FollowersFollow
13,100SubscribersSubscribe

CMS Proposes New Reimbursement Rate for CAR T-Cell Therapies

The Centers for Medicare and Medicaid Services (CMS) has proposed a new system for calculating reimbursement rates for hospitals administering chimeric antigen receptor (CAR)...

28 Million Elective Surgeries Worldwide Estimated to be Delayed by COVID-19

A study published in the British Journal of Surgery estimates that 28.4 million elective surgeries worldwide could be canceled or postponed in 2020 because...

New Data on SARS-CoV-2-Reactive T Cells Provide Insights into Immunity

Two new studies found that patients with COVID-19, as well as some people who have not been infected with SARS-CoV-2, possess T-cells that target...

Omidubicel Shows Efficacy for Patients Requiring Transplant

A clinical safety and efficacy trial of omidubicel, an investigational cell therapy for patients in need of allogeneic hematopoietic cell transplantation, achieved its primary...

FDA Announces Plan to Relaunch Onsite Facility Inspections

The FDA has announced a partnership with the Centers for Disease Control and Prevention (CDC) to develop a plan for relaunching surveillance inspections. The...